A BSTRACT
The T-cell response defi nes the pathogenesis of many common chronic disease states, including diabetes, rheumatoid arthritis, and transplant rejection. Therefore, a diagnostic strategy that visualizes this response can potentially lead to early therapeutic intervention, avoiding catastrophic organ failure or prolonged sickness. In addition, the means to deliver a drug dose to those cells in situ with the same specifi city used to image those cells would provide for a powerful therapeutic alternative for many disease states involving T cells. In this report, we review emerging nanosystems that can be used for simultaneous tracking and drug delivery to those cells. Because of their versatility, these systems -which combine specifi c receptor targeting with an imaging agent and drug delivery -are suited to both basic science and applications, from developing therapeutic strategies for autoimmune and alloimmune diseases, to noninvasive tracking of pathogenic T-cell migration.
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MIGRATION OF T CELLS
While the normal traffi cking of circulating T cells is critical for a healthy immune response, these cells occasionally become pathogenic, with disastrous consequences. [1] [2] [3] [4] [5] In healthy individuals, these cells traffi c from circulation to tissue, then to lymphatics and back to circulation ( Figure 1 ). They do this in high numbers and at different speeds throughout the blood and tissue. 5 , 6 Aberrant function at the specifi c sites of interaction or an abnormal migration pattern may dictate the pathogenesis of a variety of disease states. Table 1 shows some disease states associated with aberrant T-cell function and the epitopes recognized by those specifi c T cells during migration.
While the migration of cells through the various microenvironments is orchestrated by a complex set of interactions (which are beyond the scope of this review), 7 , 8 it is important to note that, for the purpose of imaging and modulation by drug delivery, T cells are moving targets. Nanosystems that bind to these targets in a specifi c manner may offer a powerful approach to imaging the T cells ' movement and delivering a therapeutic drug dose. The ideal nanosystems, therefore, must possess certain properties (eg, small size for internalization, multivalent attachment for enhanced avidity of interaction with cells, visibility by invasive and noninvasive modalities, high drug dose -carrying capacity, control over drug release, safety) to allow for translational applications in humans.
T-CELL TARGETING: BACKGROUND AND LIMITATIONS OF CURRENT APPROACHES
Specifi city in the T-cell response defi nes the pathogenesis of many common chronic, autoimmune, and alloimmune disease states and is mediated by the interaction of the T-cell antigen receptor (TCR) with peptide-presenting major histocompatibility complex (peptide/MHC) on the antigenpresenting cell. 7 , 9 Thus, the TCR -peptide/MHC interaction is a critical target in the immune response. The inherent low affi nity of the TCR for the peptide/MHC (1-100 um) 10 , 11 has precluded the use of soluble peptide MHC monomers for direct detection of antigen-specifi c T cells. Detection of these subsets is critical for assessing the extent of the T-cell immune response and the onset of disease. Thus, artifi cial constructs with multivalent peptide/MHCs, which bind the TCR with enhanced avidity, have had a profound impact on the understanding and characterization of the T-cell immune response at the experimental and clinical levels. [12] [13] [14] These dimeric and tetrameric forms of the MHC have been used effectively in quantitation and enumeration of a variety of T-cell types in different basic and clinical settings.
While the ability to track T cells and antigen-specifi c T cells in vitro and in vivo would be helpful for understanding the genesis of disease states involving T-cell recruitment, 14 , 15 the added ability to modulate these cells would lead to novel approaches for repairing immune system defects and restoring immune competence. Perhaps the most common strategy for modulating the antigen-specifi c T-cell response in vivo involves the induction of antigen-specifi c T-cell unresponsiveness or anergy by exposure to controlled doses of antibodies or peptide/major histocompatibility ligands (peptide/MHC). 16 However, in this approach, affected T cells remain alive in a hyporesponsive state that can be reversed by the absence of antigen or the presence of cytokines. Thus, in most cases a continuous anergic response requires multiple treatments with antigens. A second approach involves the conjugation of T-cell antigens to immunosuppressive drugs, which would serve to direct drug delivery to a targeted population of T cells. 17 But conjugation of drug to carrier antigens requires chemical modifi cations that are not always easy to achieve. In addition, the effectiveness of conjugates is often limited because it is diffi cult to provide unhindered antigen presentation together with effective drug delivery.
Clearly, a multifunctional molecular scaffold that delivers drug specifi cally to T-cell populations of interest -but in addition could be engineered for imaging of the targeted T-cell population -would offer substantial benefi ts over current approaches. In this review, we focus on 3 types of systems that may accomplish this goal: liposomal systems, dendrimers, and solid biodegradable nanoparticles.
TRACKING T-CELL TRAFFICKING AND MIGRATION
A variety of cellular imaging techniques have been developed to track the distribution and locomotion of T cells in vivo ( Table 2 ). All techniques aim to increase the signal difference between the cells and the background using either an ex vivo approach (where cells are isolated and labeled with specifi c markers, then reintroduced into the body and tracked by a variety of modalities) or an in vivo approach (in which T cells are targeted with injection of tagged antibodies or specifi c ligands).
The classical technique involving histological analysis of tissue and fl uorescent labeling of tissue sections with congenic markers specifi c for T cells has a long history of use in identifying T-cell migration to various tissue sites. 18 , 19 Indeed, this technique was used after sectioning a whole animal to identify global distribution of antigen-specifi c T cells during an immune response 20 , 21 and has yielded valuable information regarding the frequency and phenotypes of T-cell traffi cking in response to antigen challenges. But while histology provides superior spatial resolution in local microenvironments, it is severely limited in its ability to resolve dynamic changes. In addition, the labor associated with sectioning a whole animal is enormous and costly, so this technique is not used for routine analysis in laboratory investigative work.
Less invasive, high-resolution techniques such as intravital 2-photon fl uorescence microscopy have been used to track ex vivo fl uorescently labeled T cells implanted into tissue. [22] [23] [24] These studies have revealed the autonomous nature of T-cell traffi cking in lymph nodes and spleen: cells move by random walk rather than by guidance. 24 More important, the studies have shown that T cells are not stationary, waiting for chance encounters with antigen, but rather are highly motile, rapidly pacing and scanning for antigen in lymphoid organs. 24 The implications of these studies from the standpoint of cellular immunology has been extensively reviewed, and we refer the reader to those reports for further information. 7 , 18 , 22 For the purpose of this review, however, the practical application of this imaging modality in the clinic and for routine investigations in laboratory animals is limited because of its invasive nature as well as its ability to image only exposed superfi cial or explanted tissue.
To overcome this limitation, other imaging modalities have been investigated. For example, T cells labeled with radioisotopes such as [18F] 2-fl uorodeoxyglucose 25 and 99mTc-hexamethylpropyleneamine oxime 26 have been used to study lymphocyte traffi cking by positron emission tomography (PET). While this approach offers the potential to track T cells in deep tissue, it is limited in the dynamic time frame needed to visualize T-cell traffi cking because of the short half-life of the isotopes. Repeated injections and the use of tracers with longer half-lives may be possible in animal models but would not be feasible for translational use in humans.
An alternative safer method for in vivo lymphocyte visualization uses bioluminescence. 27 , 28 Because most cells lack natural fl uorescence, bioluminescence has been used to track T cells after transfection with a bioluminescent marker such as luciferase. Recent studies have documented T-cell tracking to subcutaneously implanted tumors and the traffi cking of T cells to infl amed tissue in models of autoimmune disesase. 29 , 30 The advantage of this approach over invasive techniques is that it offers the potential for imaging T-cell traffi cking deep into the body and with minimal perturbation of tissue. However, it is limited in its spatial resolution because of the poor visibility of emitted light from deep tissue and the lack of conventional instrumentation that may be used for light amplifi cation.
Of the different imaging systems available to researchers and clinicians, magnetic resonance (MR) imaging and PET offer the best potential for noninvasive imaging deep into tissue, high sensitivity, and spatiotemporal resolution through the use of appropriate contrast agents. For a detailed comparison, please see reviews by Herschman 31 and Sosnovik. 32 In this review, we will focus specifi cally on the use of MR imaging for T-cell tracking. The MR signal strength is directly related to the relaxation rates of protons in the local environment (R 1 , the longitudinal relaxation rate, and R 2 , the transverse relaxation rate). Because of this correlation, agents that enhance the rate of either type of relaxation can be used as MR contrast agents. The 2 most widely used contrast agents for cellular tracking are gadolinium-based agents, which are T 1 contrast agents that cause positive contrast enhancement and provide brighter images on accumulation in the target site, and superparamagnetic iron oxide particles, which are T 2 contrast agents that give negative contrast enhancement and thus darker images in areas of accumulation. Because nonspecifi c internalization by T cells is ineffi cient, contrast labeling of those cells requires tagging with internalization enhancers such as peptides or specifi c ligands that facilitate the internalization of the contrast agent without compromising cellular function. A variety of these internalization enhancers have been proposed and used effectively, including HIV tat peptides (which can increase T-cell uptake of liposomal 33 and iron oxide nanoparticles 34 100-fold compared with unlabeled contrast agent), anionic iron oxide nanoparticles, 35 and transfection reagents combined with the contrast agent. 36 But while supermagnetic iron oxide (SPIO) and gadoliniumbased agents are well-established, safe, and effective MR contrast agents, little has been achieved from the standpoint of incorporating these contrast agents into drug delivery vehicles for targeting specifi c T cells. A variety of other nanosystems have been developed that can potentially achieve this drug delivery, including (1) liposomal-based systems; (2) macromolecular systems such as dendrimers; and (3) solid nanoparticles, such as those fabricated from biocompatible polymers ( Figure 2 ).
NANOSYSTEMS
Liposomal Systems
Liposomes as drug delivery vehicles were fi rst proposed by Gregoriadis [37] [38] [39] [40] but have also been studied extensively for the purposes of noninvasive imaging (see reviews by Laverman et al, 41 Mulder et al, 42 and Torchilin 43 ). Liposomes are generally composed of amphiphilic phospholipids and cholesterol that self-associate into bilayers encapsulating an aqueous interior. These can be formulated into small structures (between 80 and 100 nm) that encapsulate either hydrophilic drugs in the aqueous interior or hydrophobic drugs within the bilayer ( Figure 2 ). Encapsulation is achieved using a variety of loading methods, most notably the pH gradient method (used for loading vincristine) 44 or the ammonium sulfate method (used for loading doxorubicin). 45 Additionally, the liposome surface can be engineered to improve its properties. 46 , 47 Thus far, the most noteworthy surface modifi cation is the incorporation of the hydrophilic polymer polyethylene glycol (PEG), which serves as a barrier preventing interactions with plasma proteins, thus retarding recognition by the reticuloendothelial system 48 and enhancing the liposome circulation lifetime. As a carrier for imaging agents, liposomes have proven to be versatile as well. 43 , 49 For example, liposomes have been loaded with fl uorochromes and targeted to both T-cell and B-cell lymphocytes for in vitro characterization. They have also been used in scintigraphic imaging of lymph nodes and infl ammation 41 , 50 by loading with radionuclides such as technetium99m 51 or inidium-111 52 , 53 as well as targeted imaging of tumor development and drug delivery to those tumors. 43 , 53 The combination of targeting specifi city, improved pharmacokinetic distribution, and the ability to incorporate a variety of agents into either the bilayer or the interior has led to an increased study of liposomal systems for enhancement of contrast in MR imaging. Paramagnetic reagents such as gadolinium-based chelates, manganese chloride, and iron oxide have been prepared in liposomal formulations and used to target different tissue types and cells. 42 Incorporation of the gadolinium-chelating lipids into the lipid bilayer during liposome formulation improves the relaxivity owing to enhanced water exchange with the surrounding environment and subsequent shortening of the relaxivity of the target of interest. Magnetoliposomes, which are liposomes that either incorporate iron oxide in the aqueous interior 54 , 55 or incorporate iron oxide nanoparticles coated with a lipid bilayer, 56 are effective T2 contrast agents that can be potentially engineered to release drug on exposure to a high-frequency magnetic fi eld. These systems have been used for selective targeting and MR imaging of peripheral blood monocytes. 54 It is the fl exibility of engineering and construction that makes liposomal vehicles effective candidates for noninvasive imaging. As targeted drug delivery vehicles, some limitations of liposomes have emerged: most notably, poor control over release of the drug from the liposome (ie, the potential of leakage of drug into the blood), as well as questions regarding encapsulation effi ciency, method scalability, and stability during storage. 57 , 58 Perhaps because of these limitations, the use of liposomes as combined contrast agents for T-cell tracking as well drug delivery has not been widely explored.
Macromolecular Systems: Dendrimers
Dendrimers are a class of monodisperse polymers distinguished by their repeated branching structure emanating from a central core. 59 This branching, which is inherent in the divergent synthesis of dendrimers, leads to a geometric growth of the polymer that can nearly approximate a sphere with increased branchings or higher generations (generation 6 or above). Additionally, the branching creates a labyrinthine core ideally suited for entrapment of a variety of small molecules such as drugs. 60 , 61 This fractal-like structure also creates a highly functionalized terminal surface suited for conjugation to ligands; this surface may facilitate targeting of the dendrimer or conjugation to contrast agents for imaging. As a result of these properties -and combined with their narrow molecular weight distribution and small size (less than 100 nm) -dendrimers have been used for a large number of applications, including drug delivery and contrast enhancement in MR applications. [62] [63] [64] Polyamidoamine (PAMAM) dendrimers, synthesized by the repetitive addition of branching units to an amine core such as an ammonia or ethylene diamine, are widely used for drug delivery and imaging applications. PAMAM cores can function as drug reservoirs and have been studied as vehicles for small drugs, 60 , 65-67 paramagnetic molecules for contrast enhancement in MR imaging, 63 oligonucleotides, 68 transgenes, 69 , 70 and radionuclides. 71 Recently, the combined use of paramagnetic chelates and fl uorescent groups conjugated to the surface of PAMAM dendrimers have facilitated dual-mode imaging of lymph nodes by both MR imaging and fl uorescence microscopy. 72 , 73 Because of the high number of functional groups on the termini combined with their potential for effective drug delivery, dendrimers have been exploited for targeting and visualization of a variety of tissue and cell types: by conjugation to folic acid for targeting tumors, 74 prostate-antigen-specifi c antibodies for targeting the prostate, 75 and peptides for targeting vascular endothelium 76 and intestinal epithelium. 77 One strategy for constructing T-cell binding dendrimers couples streptavidin to the termini of PEG chains tethered to the dendrimer core. In this strategy, streptavidin is used to facilitate the coupling of biotinylated T-cell markers such as biotinylated anti-CD3 or peptide/MHC complexes that target polyclonal T cells and antigen-specifi c T cells, respectively. 78 The PEG tethered to the core and terminated with a functional group facilitates fl exibility of attached ligands and allows attached proteins to scan a few nanometers of surface area for attachment to cell surface receptors. This is critical for enhancing the avidity to T-cell targets. In addition, this modifi cation provides for enhanced solubility, biocompatibility, lower immunogenicity, and desirable pharmacokinetics, while the main biological functions such as receptor recognition are maintained. [79] [80] [81] Our work has examined the utility of dendrimers in delivering doxorubicin, a widely used antiproliferative agent, to proliferating T cells and antigen-specifi c T cells. We found that the small size of the dendrimers, which allows for their effi cient internalization, coupled with their ability to deliver a large number of doxorubicin molecules to specifi c T cells, led to an effi cient system for inhibiting the specifi c proliferation of both polyclonal and antigen-specifi c T cells. 78 In addition to dendrimers ' utility as drug delivery vehicles to specifi c T-cell populations, several studies have now established their effi cacy as contrast agents in MR imaging. 78 , 82 , 83 Our work has shown the potential of using these reagents in tracking the distribution of antigen-specifi c T cells ( Figure 3 ). In these studies we compared the distribution of targeted dendrimer contrast agent in a transgenic mouse (OT-1) that expressed the OT-1 T-cell receptor specifi c for the peptide/MHC complex (H-2K b loaded with the ovalbumin peptide) and in a negative control mouse with an identical genetic background lacking the OT-1 receptor transgene. These experiments involved injection of small quantities of gadolininum-diethylene triamine pentaacetic acid (Gd-DTPA)-pegylated PAMAM conjugated to the peptide/MHC complex via the tail vein of wild-type and transgenic mice; 3-dimensional MR images were acquired between 0 and 30 minutes after injection and posteuthanasia.
Interestingly, the reagent showed longevity (up to 30 minutes and postmortem) in the heart and lungs of the transgenic mouse, while it was quickly cleared by biliary excretion (gall bladder uptake) from the wild-type mouse of identical background. This enhanced residence time and distribution were verifi ed immediately after acquisition by fl uorescence measurements of blood pools and of splenocytes dissected from both mice after euthanasia. The results also show that, consistent with previous data obtained by histological analysis, 20 antigen-experienced T cells may reside in and traffi c heavily in nonlymphoid tissues. Perhaps the most encouraging aspect of these data is that the same construct was effective in noninvasive imaging and drug delivery to antigen-specifi c T cells, highlighting the promise of these systems for both functions. 
Solid Biodegradable Nanoparticles
Solid biodegradable nanoparticulates fabricated from natural constituents such as proteins or lipids or synthetic polymers have been widely studied for targeted drug delivery to different types of cells. Emerging applications are now beginning to use some of these systems for imaging purposes. The main classes of these systems are based on either natural systems such as proteins conjugated to MR contrast agents or artifi cial polymers incorporating paramagnetic agents. Protein systems such as albumin-Gd-DTPA, while now available commercially, have had drawbacks such as limitations in routine and consistent synthesis of agents that possess similar chemical characteristics. In addition, the conformational changes, molecular shape, and size are diffi cult to predict or control. Albumin and other polypeptides are also limited in their drug delivery potential since only a few sites are available for conjugation to drugs and the potential for sustained drug delivery is low.
We focus here on one of the most widely used types of synthetic polymers, which are the aliphatic polyesters, specifically the hydrophobic poly(lactic acid) (PLA), the more hydrophilic poly(glycolic acid) (PGA), and their copolymer, poly(lactide-co-glycolide) (PLGA). These are attractive drug delivery vehicles because the degradation rate of these polymers, and the corresponding drug release rate, can vary from days (PGA) to months (PLA) and are easily manipulated by varying the ratio of PLA to PGA. 84 The drug can be encapsulated by a wide range of techniques, ranging from hydrophobic entrapment to conjugation to the polymer, providing further versatility in dosing. Moreover, the physiologic compatibility of PLGA and its homopolymers PGA and PLA have been established for safe use in humans; these materials have been used for more than 30 years in various human clinical applications, including drug delivery systems. 85 , 86 For in vivo drug delivery to lymphocytes, the delivery of immunosuppressives from biodegradable nanoparticles can improve drug effi cacy over that of free, unencapsulated drug for a variety of reasons. 70 , 87 One mechanism may simply be the sustained release of drug from localized drug reservoirs; particles that are not cleared away and release low levels of drug over a long time period have been shown to be more effective than bolus doses, presumably because even with localized bolus injections a higher percentage of free drug is cleared before any effect is exerted. In the case of nanoparticles, which are capable of being internalized by lymphocytes because of their small size, internalized PLGA nanoparticles can act as intracellular drug reservoirs, leading to continued exposure to and action of drugs over a sustained period of time. As expected, preliminary work has shown that encapsulation in nanoparticles can lower the IC 50 of doxorubicin with a variety of cell lines and even increase effi cacy in cells displaying multidrug resistance. 70 , 88 As further evidence of the benefi ts of controlled release from nanoparticles, we have shown that particles improve the biological activity of doxorubicin to target T cells ( Figure 4 ).
Targeting and controlled release would be an ideal combination for drug delivery, as the benefi ts of sustained and controlled release could be maximally exploited to increase intracellular drug concentrations, improve delivery to intracellular sites of drug activity, and bypass certain mechanisms of drug resistance. Control of drug release from internalized or localized PLGA nanoparticles is of further interest, as the benefi ts of sustained and controlled release can be used to modulate the rate, duration, and amount of intracellular drug concentration. The importance of controlled release has been seen with targeted liposomes, whose lack of ability to control release signifi cantly limits their performance. For example, a few groups have dem- onstrated that intracellular drug concentrations can be greatly increased with doxorubicin-loaded liposomes targeted to internalizing receptors. Goren et al note, however, that the in vitro effi cacy of doxorubicin is not necessarily improved, despite high intracellular concentrations. 48 They hypothesized that the drug is released by the " popping " of liposomes precipitated in the cytosol, which negates their effi cacy and suggests that the total amount of intracellular doxorubicin delivered and the rate at which it is delivered are important to consider when designing targeted delivery.
On the other hand, when release can be controlled, substantial improvements in effectiveness are possible. Targeted PLGA nanoparticles that provide a controlled release of doxorubicin to target T cells are more potent at killing cytotoxic T lymphocytes ( Figure 4 ). Based on this and other evidence, we believe that the rate and extent of duration of release from particles will be an important determinant of effi cacy for T-cell drug delivery.
In addition to targeted drug delivery, recent work has demonstrated the viability of engineering different imaging modalities into biodegradable PLGA particles, rendering them detectable by fl uorescence microscopy and MR imaging. 89 For example, recent work has shown that coencapsulation of Gd-DTPA with a fl uorescent dye such as nile red in biodegradable PLGA particles enabled noninvasive monitoring of their local intravesical delivery with MR imaging for at least 5 days after the initial instillation, although the enhancement decreased because of microparticle degradation. 89 Our work has coupled T 1 contrast agents into PLGA nanosystems for visualization of the location of the drug dose ( Figure 4 ). These systems use high-density surface modifi cation with avidin-fatty acids that maintain a display of tethered ligands for prolonged periods, potentially enhancing contrast over long periods of time and overcoming issues related to the loss of imaging contrast with particle degradation. 78 PLGA systems are therefore clearly multifunctional and as such are promising candidates for simultaneous drug delivery and imaging to various types of cells and tissues. To our knowledge little has been done using these systems for targeting drug or MR contrast agents to lymphocytes.
CONCLUSIONS AND CHALLENGES
Most noninvasive tracking approaches for T cells in the body aim for isolation of those cells; ex vivo labeling with " molecular beacons " such as bioluminescent markers, PET, or MR contrast agents; and then injection of labeled cells into the whole body and analysis of their traffi cking dynamics and localization. This information is important for diagnostic assessment of the many disease states that involve aberrant T-cell migration to tissue sites. Dextrancoated superparamagnetic iron oxide and other iron oxidebased nanoparticulates have emerged as leading candidates for this approach because of their high magnetic susceptibility coupled with the versatility in their coating with ligands that facilitate binding to target cells. This is a productive step forward in noninvasive cellular imaging; however, for tracking pathogenic lymphocytes combined with the potential for therapeutic intervention, other targeted nanosystems such as the ones discussed in this review offer considerable potential. These new capabilities may allow restoration of immune competence involving pathogenic lymphocytes and offer the potential for tracking the location and as well as localizing the drug depot to target T cells. Challenges in using these systems for routine monitoring and therapy include properly optimizing the surface to evade nonspecifi c endocytosis, understanding their clearance, and further evaluating their systemic toxicity and pharmacokinetics.
